Share Price and Basic Stock Data
Last Updated: September 3, 2024, 11:03 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ortin Laboratories Ltd operates within the pharmaceuticals sector, primarily focusing on the production and distribution of pharmaceutical products. The company reported a market capitalization of ₹16.4 Cr, with its share price standing at ₹20.1. Revenue trends over recent quarters indicate a significant decline, with sales recorded at ₹1.76 Cr in March 2021, peaking at ₹2.62 Cr in June 2022, but subsequently falling to ₹0.14 Cr by December 2023. This downward trend in sales culminated in a trailing twelve-month (TTM) revenue of ₹2.28 Cr for March 2024, down from ₹6.00 Cr in March 2023. The volatility in sales reflects operational challenges, particularly in managing production and distribution channels amid a competitive landscape.
Profitability and Efficiency Metrics
The profitability metrics of Ortin Laboratories Ltd present a concerning picture. The company reported a net profit of -₹8.04 Cr for the year ending March 2024, a decline from -₹0.09 Cr in the previous year. This downturn is further illustrated by an operating profit margin (OPM) of -1,016.67% in March 2024, indicating severe operational inefficiencies. The return on equity (ROE) stood at an impressive 118%, while the return on capital employed (ROCE) was recorded at 60.2%, showcasing the potential efficiency of its capital utilization despite the negative profit figures. The interest coverage ratio (ICR) of 3.63x suggests that the company can cover its interest obligations comfortably, yet the negative net profits raise concerns about long-term sustainability and operational effectiveness.
Balance Sheet Strength and Financial Ratios
Ortin Laboratories Ltd’s balance sheet reflects a challenging financial position, with total liabilities amounting to ₹6.59 Cr against total assets of the same value, indicating a precarious balance between assets and liabilities. The company reported reserves of -₹5.31 Cr, a stark decline from ₹2.73 Cr in March 2023, highlighting significant financial distress. Borrowings stood at ₹1.80 Cr, down from ₹6.45 Cr in the previous year, suggesting a reduction in financial leverage. The price-to-book value (P/BV) ratio is 1.97x, indicating that the shares are trading near their book value, which may appeal to value investors. However, the lack of positive retained earnings raises red flags about future growth prospects and the firm’s ability to reinvest in its operations.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ortin Laboratories Ltd remains opaque, with no available data on the distribution among promoters, foreign institutional investors (FIIs), domestic institutional investors (DIIs), or the public. This lack of transparency complicates the assessment of investor confidence and market sentiment towards the company. Given the reported net loss and declining revenues, investor sentiment may be adversely affected, leading to potential volatility in the stock price. The absence of significant institutional backing could also indicate a lack of confidence from larger investors, which typically play a crucial role in stabilizing share prices during turbulent times. The market’s reaction to these financial challenges will be critical for Ortin as it navigates its operational hurdles.
Outlook, Risks, and Final Insight
Looking ahead, Ortin Laboratories Ltd faces significant challenges that may impede recovery. The declining sales and profitability metrics suggest that without strategic operational changes, the company risks further deterioration of its financial health. Key strengths include its high return on equity and manageable interest coverage ratio, which could provide a cushion if the company can stabilize its operations. However, significant risks remain, including negative reserves and ongoing operational inefficiencies. The company must address these issues to regain investor confidence and improve its financial standing. In scenarios where Ortin can effectively streamline operations and enhance product offerings, it may find avenues for recovery and growth; conversely, failure to do so could lead to deeper financial distress and potential insolvency. The upcoming quarters will be critical in determining the company’s trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 127 Cr. | 101 | 197/84.3 | 28.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,378 Cr. | 310 | 479/192 | 70.0 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.7 Cr. | 45.4 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 69.6 Cr. | 47.5 | 47.6/17.0 | 166 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,348.44 Cr | 1,074.12 | 47.21 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.76 | 1.98 | 2.29 | 1.66 | 2.45 | 2.62 | 0.79 | 1.17 | 1.49 | 1.57 | 0.27 | 0.14 | 0.30 |
| Expenses | 1.55 | 1.61 | 2.00 | 1.65 | 2.59 | 2.41 | 1.01 | 0.55 | 1.52 | 1.39 | 1.17 | 2.74 | 3.35 |
| Operating Profit | 0.21 | 0.37 | 0.29 | 0.01 | -0.14 | 0.21 | -0.22 | 0.62 | -0.03 | 0.18 | -0.90 | -2.60 | -3.05 |
| OPM % | 11.93% | 18.69% | 12.66% | 0.60% | -5.71% | 8.02% | -27.85% | 52.99% | -2.01% | 11.46% | -333.33% | -1,857.14% | -1,016.67% |
| Other Income | 0.05 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.19 | 0.18 | 0.19 | 0.19 | 0.24 | 0.10 | 0.09 | 0.10 | 0.12 | 0.11 | 0.15 | 0.14 | 0.08 |
| Depreciation | 0.07 | 0.07 | 0.07 | -0.07 | 0.23 | 0.07 | 0.07 | 0.07 | 0.03 | 0.06 | 0.06 | 0.06 | 0.05 |
| Profit before tax | 0.00 | 0.12 | 0.07 | -0.11 | -0.61 | 0.04 | -0.38 | 0.45 | -0.21 | 0.01 | -1.11 | -2.80 | -3.18 |
| Tax % | 25.00% | 28.57% | -18.18% | -24.59% | 1,150.00% | -121.05% | 0.00% | -4.76% | 0.00% | 1.80% | -0.71% | 30.19% | |
| Net Profit | 0.80 | 0.09 | 0.05 | -0.09 | -0.45 | -0.43 | 0.08 | 0.46 | -0.20 | 0.02 | -1.12 | -2.79 | -4.14 |
| EPS in Rs | 0.98 | 0.11 | 0.06 | -0.11 | -0.55 | -0.53 | 0.10 | 0.57 | -0.25 | 0.02 | -1.38 | -3.43 | -5.09 |
Last Updated: Unknown
Below is a detailed analysis of the quarterly data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Sales, as of Mar 2024, the value is 0.30 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Dec 2023) to 0.30 Cr., marking an increase of 0.16 Cr..
- For Expenses, as of Mar 2024, the value is 3.35 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.74 Cr. (Dec 2023) to 3.35 Cr., marking an increase of 0.61 Cr..
- For Operating Profit, as of Mar 2024, the value is -3.05 Cr.. The value appears to be declining and may need further review. It has decreased from -2.60 Cr. (Dec 2023) to -3.05 Cr., marking a decrease of 0.45 Cr..
- For OPM %, as of Mar 2024, the value is -1,016.67%. The value appears strong and on an upward trend. It has increased from -1,857.14% (Dec 2023) to -1,016.67%, marking an increase of 840.47%.
- For Other Income, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2023) which recorded 0.00 Cr..
- For Interest, as of Mar 2024, the value is 0.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.14 Cr. (Dec 2023) to 0.08 Cr., marking a decrease of 0.06 Cr..
- For Depreciation, as of Mar 2024, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.06 Cr. (Dec 2023) to 0.05 Cr., marking a decrease of 0.01 Cr..
- For Profit before tax, as of Mar 2024, the value is -3.18 Cr.. The value appears to be declining and may need further review. It has decreased from -2.80 Cr. (Dec 2023) to -3.18 Cr., marking a decrease of 0.38 Cr..
- For Tax %, as of Mar 2024, the value is 30.19%. The value appears to be increasing, which may not be favorable. It has increased from -0.71% (Dec 2023) to 30.19%, marking an increase of 30.90%.
- For Net Profit, as of Mar 2024, the value is -4.14 Cr.. The value appears to be declining and may need further review. It has decreased from -2.79 Cr. (Dec 2023) to -4.14 Cr., marking a decrease of 1.35 Cr..
- For EPS in Rs, as of Mar 2024, the value is -5.09. The value appears to be declining and may need further review. It has decreased from -3.43 (Dec 2023) to -5.09, marking a decrease of 1.66.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: Unknown
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74.74 | 67.00 | 60.29 | 62.72 | 61.57 | 79.63 | 167.51 | 197.36 | 8.16 | 8.23 | 6.00 | 2.28 |
| Expenses | 68.17 | 60.90 | 53.80 | 56.83 | 56.12 | 74.22 | 160.83 | 191.66 | 6.92 | 7.85 | 5.47 | 8.65 |
| Operating Profit | 6.57 | 6.10 | 6.49 | 5.89 | 5.45 | 5.41 | 6.68 | 5.70 | 1.24 | 0.38 | 0.53 | -6.37 |
| OPM % | 8.79% | 9.10% | 10.76% | 9.39% | 8.85% | 6.79% | 3.99% | 2.89% | 15.20% | 4.62% | 8.83% | -279.39% |
| Other Income | 0.24 | 0.81 | 0.00 | 0.57 | 0.32 | 0.45 | 0.13 | 0.18 | 0.05 | 0.19 | 0.01 | 0.00 |
| Interest | 3.55 | 3.72 | 3.52 | 3.42 | 2.94 | 3.49 | 3.22 | 3.21 | 0.87 | 0.81 | 0.40 | 0.48 |
| Depreciation | 1.40 | 1.51 | 1.64 | 1.65 | 1.70 | 1.69 | 1.75 | 1.96 | 0.29 | 0.29 | 0.25 | 0.23 |
| Profit before tax | 1.86 | 1.68 | 1.33 | 1.39 | 1.13 | 0.68 | 1.84 | 0.71 | 0.13 | -0.53 | -0.11 | -7.08 |
| Tax % | 41.40% | 29.17% | 32.33% | 41.01% | 55.75% | 0.00% | 30.43% | 181.69% | -623.08% | -24.53% | -18.18% | 13.56% |
| Net Profit | 1.09 | 1.19 | 0.90 | 0.83 | 0.50 | 0.68 | 1.28 | -0.56 | 0.95 | -0.40 | -0.09 | -8.04 |
| EPS in Rs | 0.64 | 0.70 | 0.53 | 0.49 | 0.30 | 0.40 | 0.76 | -0.33 | 1.17 | -0.49 | -0.11 | -9.89 |
| Dividend Payout % | 38.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.17% | -24.37% | -7.78% | -39.76% | 36.00% | 88.24% | -143.75% | 269.64% | -142.11% | 77.50% | -8833.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -33.54% | 16.59% | -31.98% | 75.76% | 52.24% | -231.99% | 413.39% | -411.75% | 219.61% | -8910.83% |
Ortin Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: Unknown
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 16.94 | 8.13 | 8.13 | 8.13 | 8.13 |
| Reserves | 3.84 | 5.02 | 5.50 | 6.33 | 6.46 | 7.14 | 8.15 | 6.88 | 3.22 | 2.83 | 2.73 | -5.31 |
| Borrowings | 17.92 | 18.68 | 20.96 | 20.85 | 17.34 | 17.34 | 19.47 | 19.57 | 6.94 | 6.14 | 6.45 | 1.80 |
| Other Liabilities | 34.80 | 31.93 | 23.87 | 21.22 | 20.79 | 32.24 | 60.53 | 73.13 | 2.97 | 3.61 | 3.89 | 1.97 |
| Total Liabilities | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
| Fixed Assets | 24.77 | 23.90 | 21.83 | 21.63 | 20.69 | 20.03 | 21.29 | 22.45 | 14.38 | 14.21 | 13.96 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.35 | 0.40 | 0.53 | 0.43 | 0.43 | 0.43 | 0.43 | 0.00 |
| Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 48.70 | 48.64 | 45.41 | 43.68 | 40.42 | 53.15 | 83.19 | 93.57 | 6.45 | 6.07 | 6.81 | 6.58 |
| Total Assets | 73.50 | 72.57 | 67.27 | 65.34 | 61.53 | 73.66 | 105.09 | 116.52 | 21.26 | 20.71 | 21.20 | 6.59 |
Below is a detailed analysis of the balance sheet data for Ortin Laboratories Ltd based on the most recent figures (Mar 2024) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2024, the value is 8.13 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 8.13 Cr..
- For Reserves, as of Mar 2024, the value is -5.31 Cr.. The value appears to be declining and may need further review. It has decreased from 2.73 Cr. (Mar 2023) to -5.31 Cr., marking a decrease of 8.04 Cr..
- For Borrowings, as of Mar 2024, the value is 1.80 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 6.45 Cr. (Mar 2023) to 1.80 Cr., marking a decrease of 4.65 Cr..
- For Other Liabilities, as of Mar 2024, the value is 1.97 Cr.. The value appears to be improving (decreasing). It has decreased from 3.89 Cr. (Mar 2023) to 1.97 Cr., marking a decrease of 1.92 Cr..
- For Total Liabilities, as of Mar 2024, the value is 6.59 Cr.. The value appears to be improving (decreasing). It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
- For Fixed Assets, as of Mar 2024, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 13.96 Cr. (Mar 2023) to 0.01 Cr., marking a decrease of 13.95 Cr..
- For CWIP, as of Mar 2024, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.43 Cr. (Mar 2023) to 0.00 Cr., marking a decrease of 0.43 Cr..
- For Investments, as of Mar 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2023) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2024, the value is 6.58 Cr.. The value appears to be declining and may need further review. It has decreased from 6.81 Cr. (Mar 2023) to 6.58 Cr., marking a decrease of 0.23 Cr..
- For Total Assets, as of Mar 2024, the value is 6.59 Cr.. The value appears to be declining and may need further review. It has decreased from 21.20 Cr. (Mar 2023) to 6.59 Cr., marking a decrease of 14.61 Cr..
However, the Borrowings (1.80 Cr.) are higher than the Reserves (-5.31 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -11.35 | -12.58 | -14.47 | -14.96 | -11.89 | -11.93 | -12.79 | -13.87 | -5.70 | -5.76 | -5.92 | -8.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
No data available for the Shareholding
No data available for the Shareholding Pattern chart.
No data available for the No. of Shareholders chart.
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 12 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 2.73 |
| Diluted EPS (Rs.) | 2.73 |
| Cash EPS (Rs.) | 3.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.47 |
| Revenue From Operations / Share (Rs.) | 50.63 |
| PBDIT / Share (Rs.) | 6.99 |
| PBIT / Share (Rs.) | 6.13 |
| PBT / Share (Rs.) | 4.20 |
| Net Profit / Share (Rs.) | 2.73 |
| NP After MI And SOA / Share (Rs.) | 2.73 |
| PBDIT Margin (%) | 13.81 |
| PBIT Margin (%) | 12.10 |
| PBT Margin (%) | 8.30 |
| Net Profit Margin (%) | 5.38 |
| NP After MI And SOA Margin (%) | 5.38 |
| Return on Networth / Equity (%) | 18.85 |
| Return on Capital Employeed (%) | 34.77 |
| Return On Assets (%) | 5.67 |
| Long Term Debt / Equity (X) | 0.11 |
| Total Debt / Equity (X) | 0.58 |
| Current Ratio (X) | 1.11 |
| Quick Ratio (X) | 0.82 |
| Interest Coverage Ratio (X) | 3.63 |
| Interest Coverage Ratio (Post Tax) (X) | 2.42 |
| Enterprise Value (Cr.) | 62.39 |
| EV / Net Operating Revenue (X) | 0.72 |
| EV / EBITDA (X) | 5.27 |
| MarketCap / Net Operating Revenue (X) | 0.56 |
| Price / BV (X) | 1.97 |
| Price / Net Operating Revenue (X) | 0.56 |
| EarningsYield | 0.09 |
After reviewing the key financial ratios for Ortin Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 12, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 12, the value is 2.73. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 12, the value is 3.59. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 12, the value is 14.47. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 12, the value is 50.63. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 12, the value is 6.99. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 12, the value is 6.13. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 12, the value is 4.20. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 12, the value is 2.73. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 12, the value is 13.81. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 12, the value is 12.10. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 12, the value is 8.30. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 12, the value is 5.38. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 12, the value is 5.38. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 12, the value is 18.85. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 12, the value is 34.77. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 12, the value is 5.67. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 12, the value is 0.11. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 12, the value is 0.58. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 12, the value is 1.11. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 12, the value is 0.82. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 12, the value is 3.63. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 12, the value is 2.42. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 12, the value is 62.39. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 12, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 12, the value is 5.27. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 12, the value is 1.97. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 12, the value is 0.56. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 12, the value is 0.09. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ortin Laboratories Ltd:
- Net Profit Margin: 5.38%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 34.77% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.85% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.42
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 47.21)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.58
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.38%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | D. No. 1-8-B4, Ground Floor, F3 HIG, Block-4, Street No.3, Hyderabad Telangana 500044 | info@ortinlabsindia.com http://www.ortinlabsindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Murali Krishna Rayaprolu | Chairman & Ind.Director |
| Mr. S Murali Krishna Murthy | Managing Director |
| Mr. S Srinivas Kumar | Whole Time Director |
| Mr. S Balaji Venkateswarlu | Non Executive Director |
| Mr. B Gopal Reddy | Independent Director |
| Ms. Pottur Sujatha | Independent Director |
Ortin Laboratories Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹18.00 |
| Previous Day | ₹18.48 |
FAQ
What is the intrinsic value of Ortin Laboratories Ltd?
Ortin Laboratories Ltd's intrinsic value (as of 29 January 2026) is ₹31.28 which is 55.62% higher the current market price of ₹20.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹16.4 Cr. market cap, FY2025-2026 high/low of ₹26.4/16.2, reserves of ₹-5.31 Cr, and liabilities of ₹6.59 Cr.
What is the Market Cap of Ortin Laboratories Ltd?
The Market Cap of Ortin Laboratories Ltd is 16.4 Cr..
What is the current Stock Price of Ortin Laboratories Ltd as on 29 January 2026?
The current stock price of Ortin Laboratories Ltd as on 29 January 2026 is ₹20.1.
What is the High / Low of Ortin Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ortin Laboratories Ltd stocks is ₹26.4/16.2.
What is the Stock P/E of Ortin Laboratories Ltd?
The Stock P/E of Ortin Laboratories Ltd is .
What is the Book Value of Ortin Laboratories Ltd?
The Book Value of Ortin Laboratories Ltd is 3.47.
What is the Dividend Yield of Ortin Laboratories Ltd?
The Dividend Yield of Ortin Laboratories Ltd is 0.00 %.
What is the ROCE of Ortin Laboratories Ltd?
The ROCE of Ortin Laboratories Ltd is 60.2 %.
What is the ROE of Ortin Laboratories Ltd?
The ROE of Ortin Laboratories Ltd is 118 %.
What is the Face Value of Ortin Laboratories Ltd?
The Face Value of Ortin Laboratories Ltd is 10.0.